TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO plc announced that its client, Cidara Therapeutics, has entered into an agreement to be acquired by Merck Sharp & Dohme LLC for approximately $9.2 billion, following positive results from a Phase IIb trial of Cidara’s lead candidate, CD388. This acquisition highlights hVIVO’s role in accelerating drug development and supporting breakthrough therapies, as the company has been instrumental in the development of CD388, providing critical data and conducting large-scale field studies. hVIVO’s involvement underscores its capabilities in human challenge trials and its diversification into field studies and laboratory services, reinforcing its position in the infectious disease space.
The most recent analyst rating on (GB:HVO) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Neutral.
The overall stock score of 65 reflects strong financial performance and attractive valuation, offset by bearish technical indicators. The company’s robust revenue growth and profitability are significant strengths, while the current market momentum suggests caution. The low P/E ratio and dividend yield highlight potential undervaluation, making it appealing for value investors.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service early phase Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides end-to-end clinical development services to a diverse client base, including major biopharma companies. hVIVO specializes in conducting human challenge trials across various infectious and respiratory indications and offers comprehensive virology and immunology laboratory services. The company operates a state-of-the-art quarantine facility in London and has subsidiaries in Germany and the Netherlands, offering early-phase clinical trial services and drug development consulting.
Average Trading Volume: 2,133,668
Technical Sentiment Signal: Sell
Current Market Cap: £39.5M
Learn more about HVO stock on TipRanks’ Stock Analysis page.